Rybelsus overview
Brand name for oral semaglutide, FDA-approved for type 2 diabetes mellitus. Daily tablet (3, 7, 14 mg).
Rybelsus at a glance
Manufacturer
Novo Nordisk
FDA status
FDA-approved
Questions readers ask
What strengths does Rybelsus come in, and how is it taken?
Rybelsus is a daily oral semaglutide tablet from Novo Nordisk in 3, 7 and 14 mg strengths, FDA-approved for type 2 diabetes mellitus. This page does not list it for chronic weight management; your clinician chooses the strength.
Is there an oral GLP-1 pill sold for weight management?
Yes. The Wegovy pill costs $149, $199 or $299 a month by dose via NovoCare (read October 14, 2026). Foundayo (orforglipron), a different oral GLP-1 approved April 1, 2026, starts from $149.
Is compounded semaglutide equivalent to Rybelsus?
No. Rybelsus is FDA-approved, while compounded semaglutide is a different, unapproved preparation, and FDA has warned sellers that call it the same. FDA has also warned against the salt forms semaglutide sodium and semaglutide acetate.
Does the Medicare GLP-1 Bridge cover Rybelsus?
Rybelsus is not on the Bridge list. From July 1, 2026 to Dec 31, 2027, eligible Part D members pay a $50 copay for Wegovy, Foundayo and Zepbound KwikPen, subject to prior authorization and BMI-based criteria; open enrollment runs Oct 15 to Dec 7, 2026.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Registered outsourcing facilities (503B)
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Wegovy (semaglutide) prescribing information, Novo Nordisk